Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance.


Background Dolutegravir, an integrase strand-transfer inhibitor (STI), shows a high genetic barrier to resistance. Dolutegravir is reported to be effective against viruses resistant to raltegravir and elvitegravir. In this study, we report the case of a patient treated with dolutegravir monotherapy. Failure of dolutegravir treatment was observed concomitant… (More)
DOI: 10.1093/jac/dkx529

9 Figures and Tables


  • Presentations referencing similar topics